WASHINGTON, DC — More than 3,700 bottles of blood pressure medicine sold across the country have been recalled after federal regulators said the tablets failed a quality test tied to how they dissolve in the body. The Food and Drug Administration said the products were pulled from the market last month by New Jersey-based Macleods Pharma USA Inc.
The recalled medicine is Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide tablets, a combination prescription drug used to treat hypertension. The FDA classified the action as a Class II recall on Oct. 26, which means the problem could lead to temporary or medically reversible health effects, while the chance of serious harm is considered low.
Which bottles were included in the Macleods Pharma recall
The recall covers tablets in three strengths: 40 mg, 10 mg and 12.5 mg. They were distributed in bottles containing either 30 or 90 tablets, according to the FDA enforcement report.
In total, 3,528 bottles in the 30-count size were recalled, along with 216 bottles in the 90-count size. That adds up to 3,744 bottles nationwide.
Federal records say the affected products were part of a last-month recall action announced by the company on Oct. 7. The bottles were sold nationally, making the issue relevant to patients who may have picked up the medication in pharmacies across the United States.
Why the FDA said the tablets failed quality standards
The reason listed for the recall was “failed dissolution specifications.” In plain terms, that means the tablets did not break down and dissolve the way they were supposed to under the required test conditions.
Dissolution matters because medicine must release its ingredients properly in the body to work as intended. When a tablet does not dissolve correctly, it may not deliver the expected amount of medication, which is why regulators treat the issue as a manufacturing-quality concern.
The FDA enforcement report did not include any further explanation about how the problem was discovered or whether any adverse events had been reported. NBC Chicago said it reached out to Macleods Pharma USA Inc. for comment.
What a Class II recall means for patients taking these prescriptions
The FDA’s Class II designation signals that the risk is not considered the most severe category, but the product still may cause temporary or medically reversible health problems. That classification is often used when a defect could affect treatment without being likely to cause lasting injury.
For patients, the concern is especially important because these tablets are prescribed to manage high blood pressure. The Mayo Clinic says the drugs are used to treat hypertension, a condition that can raise the risk of serious cardiovascular problems if it is not controlled.
People who have these bottles at home should compare their prescription information with the recalled strengths and package sizes listed by the FDA. Pharmacists and prescribers can help verify whether a bottle is part of the recall and discuss next steps for replacement or disposal.
The company and regulators have released limited public detail so far
So far, the public record is limited to the FDA enforcement report and the company’s recall action. The agency did not provide additional details about whether the problem affected one batch, multiple lots, or production at a specific facility.
Macleods Pharma USA Inc., which is based in New Jersey, was identified as the recalling firm. The recall covers a common blood pressure combination medication that many patients take once daily, making the nationwide scope especially significant for routine prescription users.
With no further explanation from the company yet available, the key facts remain the date of the recall, the affected drug strengths, and the FDA’s conclusion that the tablets failed dissolution testing. That is the central quality issue driving the action.
What consumers should do if they have the recalled medication
Patients who have Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide tablets should check the bottle label for the strength and count information listed in the recall. If the packaging matches, they should contact a pharmacist or the prescribing doctor before taking the medication any further.
Because the recall is nationwide, the products may have been dispensed in different states and through different pharmacies. The safest step is to confirm the bottle against the recall details rather than assume it is unaffected.
The FDA’s notice does not mention a blanket emergency or say every bottle from the company is involved. It is specific to the recalled strengths and package counts identified in the enforcement report.
Why blood pressure medicine recalls matter beyond this one product
Medication recalls like this one draw attention because blood pressure drugs are taken regularly and often long term. Even a quality problem that is considered low risk can matter when the medicine is part of a daily treatment plan.
High blood pressure is a chronic condition, so patients may not notice a problem right away if a tablet does not dissolve correctly. That is why federal monitoring of prescription quality plays an important role in catching manufacturing defects before they affect more people.
For now, the FDA’s action means the recalled bottles should be checked carefully and handled through normal pharmacy or medical channels. The agency’s classification indicates a quality problem rather than a contamination or emergency alert, but it still warrants prompt attention from patients and health care providers.
Leave a Reply